Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Kanglaite - Zhejiang Kanglaite Pharmaceutical/KangLaiTe USA

Drug Profile

Kanglaite - Zhejiang Kanglaite Pharmaceutical/KangLaiTe USA

Alternative Names: Kanglaite gelcap; Kanglaite injection; KLT; KLTc; KLTi

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KangLaiTe USA; Zhejiang Kanglaite Pharmaceutical
  • Class Antineoplastics; Herbal medicines; Traditional Chinese medicine
  • Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants; Cell cycle inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Cancer; Liver cancer; Non-small cell lung cancer
  • Phase II Pancreatic cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cachexia in USA (IV, Injection)
  • 19 Aug 2015 Phase-II development for Pancreatic cancer and Prostate cancer is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top